This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Stealth BioTherapeutics Future Growth

Future criteria checks 0/6

Key information

3.4%

Earnings growth rate

95.1%

EPS growth rate

Biotechs earnings growth	20.7%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	n/a

Recent future growth updates

Recent updates

Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year

Dec 31

Stealth Bio launches $3.2M registered direct offering

Nov 20

Earnings and Revenue Growth Forecasts

NasdaqGM:MITO - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	N/A	-48	N/A	N/A	1
12/31/2023	N/A	-48	N/A	N/A	2
12/31/2022	N/A	-45	N/A	N/A	2
12/31/2021	N/A	-53	-45	-45	N/A
9/30/2021	N/A	-51	N/A	N/A	N/A
6/30/2021	N/A	-56	-44	-44	N/A
3/31/2021	N/A	-50	N/A	N/A	N/A
12/31/2020	N/A	-57	-54	-54	N/A
9/30/2020	21	-35	-39	-38	N/A
6/30/2020	21	-41	N/A	N/A	N/A
3/31/2020	21	-44	N/A	N/A	N/A
12/31/2019	21	-72	-48	-48	N/A
9/30/2019	N/A	-102	-75	-74	N/A
6/30/2019	N/A	-108	N/A	N/A	N/A
3/31/2019	N/A	-120	N/A	N/A	N/A
12/31/2018	N/A	-97	-72	-72	N/A
9/30/2018	N/A	-92	-69	-69	N/A
12/31/2017	N/A	-83	-70	-70	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MITO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MITO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MITO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if MITO's revenue is forecast to grow faster than the US market.

High Growth Revenue: MITO is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MITO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

This company has been acquired

Stealth BioTherapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased to US$1.78

Price target increased to US$1.78

Price target decreased to US$2.37

Price target decreased to US$3.03

Price target decreased to US$3.03

Price target decreased to US$3.00

Recent updates

Stealth BioTherapeutics Corp(NasdaqGM:MITO) dropped from NASDAQ Composite Index

J. Wood Capital Advisors LLC and Morningside Venture (I) Investments Limited completed the acquisition of 22.5293% stake in Stealth BioTherapeutics Corp (NasdaqGM:MITO).

Price target increased to US$1.78

Less than half of directors are independent

Stealth BioTherapeutics Corp Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis

Stealth BioTherapeutics Corp Announces Departure of Robert Weiskopf as Chief Financial Officer

Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company

Price target increased to US$1.78

Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private

Stealth BioTherapeutics: A Net-Net Biopharma Going Private

Stealth BioTherapeutics Announces Receipt of Non-Compliance Notice from Nasdaq

Stealth BioTherapeutics receives Nasdaq non-compliance receipt

Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome

Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium

Stealth BioTherapeutics Corp Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022

Price target decreased to US$2.37

Stealth Biotherapeutics Announces Data from Reclaim-2 Phase 2 Trial of Elamipretide in Geographic Atrophy

Price target decreased to US$3.03

Less than half of directors are independent

Stealth BioTherapeutics Corp Announces New SBT-272 Data and Trial Initiation

Price target decreased to US$3.03

Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial

Stealth BioTherapeutics Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Requirement

Stealth BioTherapetuics Receives Nasdaq Notifications Regarding Minimum Bid and Market Value Requirements

Price target decreased to US$3.00

Stealth Bio Therapeutics Provides Update on Clinical Stage Rare Disease Programs

Stealth BioTherapeutics Corp Presents Positive Elamipretide Data in Pediatric Cardiology At International Society for Heart Research North American Section Meeting 2021

Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at International Parkinson and Movement Disorder Society Virtual Congress 2021

Stealth Biotherapeutics Strengthens IP Portfolio with Issuance of U.S. Patents Covering Elamipretide for Barth Syndrome

Price target decreased to US$3.25

Stealth Biotherapeutics shares soar on EMA orphan drug status for elamipretide

Stealth Biotherapeutics Corp Showcases Data for Elamipretide in Dry Age-Related Macular Degeneration At the 2021 Arvo Annual Meeting

Stealth BioTherapeutics skyrockets on data for elamipretide studies

Consensus revenue estimates fall to US$5.00m

Stealth BioTherapeutics Corp Announces Promotion of Marty Redmon to Chief Research & Development Officer

Stealth BioTherapeutics Corp Completes Enrollment of Phase 2 Study in Dry Age-Related Macular Degeneration with Geographic Atrophy

New 90-day high: US$1.93

New 90-day high: US$1.72

Stealth BioTherapeutics Granted Pre-NDA Meeting For Elamipretide As Treatment For Cardiomyopathy In Barth Syndrome

FDA accepts Stealth Bio's Pre-NDA meeting request for elamipretide

Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year

Price target lowered to US$2.82

New 90-day high: US$1.62

Stealth BioTherapeutics Corp Announces Board and Committee Changes

Revenue and earnings in line with expectations

Stealth Bio launches $3.2M registered direct offering

Revenue and earnings in line with expectations

Stealth Biotherapeutics Announces Development Financing to Advance Elamipretide Clinical Trials

Stealth BioTherapeutics Corp to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: US$1.28

New 90-day low: US$1.32

Stealth BioTherapeutics Announces Poster Presentation at 2020 Annual NEALS Meeting

New 90-day low - US$1.50

New 90-day low - US$1.68

Stealth BioTherapeutics Corp to Report Q2, 2020 Results on Aug 06, 2020

New 90-day high - US$2.23

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies